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A B S T R A C T
The consequences of falsely reactive HIV test results can be significant, for patients and healthcare
providers. This case describes a diagnostic investigation of a patient with pronounced discordant HIV
serological results, to determine HIV status. The fourth generation serological screening assay (Roche
COBAS Elecsys HIV combiPT) had high positive results but confirmatory testing was negative (Abbott HIV
Ag/Ab Combo). Five separate samples over 13 days were tested using multiple fourth generation HIV
immunoassays and molecular tests for HIV-1 and HIV-2. Potential causes of falsely reactive serological
results were investigated. Samples were sent to the manufacturer for analysis.
The screening assay was positive on all samples with a very high signal to cut-off ratio (S/CO) of greater
than 400. However, multiple serological and molecular assays did not detect HIV-1 or HIV-2 specific
antibodies, antigen or nucleic acid. A recombinant immunochromatographic assay had faint reactivity to
gp41 peptide and the manufacturer investigation reported cross-reactivity to one of the screening assay’s
synthetic peptides. Possible causes of the false positive result include cross reactivity to other antigens,
including prior schistosomiasis infection, or the patient’s previously excised ameloblastoma (a rare germ
cell tumor of the jaw). This is a rare case of false high positive results on fourth-generation HIV serology
testing due to high level non-specific reactivity to an isolated synthetic peptide component of the assay. It
highlights the need for confirmatory testing even in settings with HIV high prevalence and awareness
that false-positive serological results may have a high S/CO.
© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Contents lists available at ScienceDirect
IDCases
journal homepage: www.elsevier .com/ locate / idcrIntroduction
A falsely reactive HIV test result has serious consequences for
patients, both emotionally and socially. It may also result in
unnecessary initiation of antiretroviral treatment, with potential
for side effects and other complications. If later proven to have
been false-positive, this can have a negative impact on the
perception of, and trust in the health care services by the public.
Most falsely reactive HIV serological result are low positive, and
can be excluded on the basis of a low positive or indeterminate
range, which is appropriate for the local population. In South
Africa, HIV testing guidelines for adults and infants over the age of
18 months recommend the use of a series of rapid* Corresponding author at: Department of Medicine, University of the
Witwatersrand, Johannesburg, South Africa.
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immunosorbent assays (ELISA) in case of discrepant rapid
results [1].
Case presentation
The patient was a 35 year old Nigerian man, living in South
Africa, who had an unremarkable medical history until 2012, and
described himself as previously fit and healthy. Regular screening
for HIV at the local community health care clinic had been
negative, including three weeks prior to his hospital admission. He
denied recent flu-like symptoms or treatment for sexually
transmitted infections. He did not use regular medications,
traditional medicine, vitamins or dietary supplements. He had
no history of HIV vaccine exposure or antiretroviral drug use for
pre- or post-exposure prophylaxis. In June 2012, he had a subtotal
hemi-mandibulectomy for an ameloblastoma, a benign odonto-
genic tumor of the mandible [2]. This was done in Nigeria,
according to the patient's self-reported history, but there is neither
a histology report nor access to the specimen to confirm the
diagnosis. After moving to South Africa, he experienced surgicalnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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mandibular reconstruction plate. In 2019, as part of his pre-surgical
assessment and workup, he had blood taken for HIV screening.
During the operation, one of the surgeons sustained a needle-stick
injury, and the virology laboratory was contacted to enquire about
the results of the HIV test requested on admission.
His regular partner was then pregnant and had tested HIV
negative multiple times during antenatal care visits, including a
week before the patient’s admission to hospital. He reported
concurrent, consistently protected casual intercourse with multi-
ple other female partners up until two to three weeks prior to the
current admission but did not report any intravenous drug use or
intercourse with men.
Serological screening for HIV-1 and HIV-2 infection was done
according to the routine virology testing algorithm at the National
Health Laboratory Service (NHLS) Tygerberg laboratory. The 4th
generation Elecsys HIV combi PT assay on the Roche COBAS1e 601
analyser (Roche Diagnostics, Mannhein, Germany) showed a
reactive result with a high signal to cut-off ratio of 478. However,
confirmatory serology using the HIV Ag/Ab Combo assay on the
Abbott Architect i2000SR analyser (Abbott Laboratories, Wiesba-
den, Germany) was non-reactive with a signal to cut-off ratio of
0.71. Both assays were repeated on four independently obtained
samples, obtained over a period of five days, as well as 12 days after
the first sample, with similar values obtained (Table 1). The Roche
Elecsys HIV combi PT assay is a sandwich electrochemilumine-
cence (ELICA) serological assay [3]. It captures HIV-1 and HIV-2
antibodies and p24 antigens, using biotinylated and ruthenylated
conjugates (anti-p24 antibodies, HIV-specific recombinant anti-
gens/ HIV-specific peptides) to form sandwich complexes,
thereafter streptavidin-coated microparticles are added to capture
the complexes. A signal is generated from the electrochemilumi-
nescent reaction and the assay readout is light, emitted by the
ruthenium complexes when a voltage is passed through the
reaction. This signal is compared to a cut off value obtained byTable 1
Serological results.
Date: April 2019 5/4 
Sample ID 1 
Instrument /platform Assay/ test
COBAS e 601 Elecsys1HIV combi PT R 
S/CO: 478 
Abbott Architect i2000SR HIV Ag/Ab Combo NR 
S/CO: 0.71 
Bio-Rad Bio-Rad Genscreen 
ULTRA HIV Ag/Ab
S/CO: 
Rapid test Visitect HIV1/2 Rapid 
Rapid test AlereTM HIV Combo 
Rapid test Abon HIV 1/2/O Tri-line 




Date: April 2019 5/4 
Sample ID 1 
Instrument /platform Assay/ test
COBAS1AmpliPrep/ HIV-1 Quantitative 
COBAS1 TaqMan Test V2.0
COBAS1AmpliPrep/ HIV-1 Qualitative 
COBAS1
TaqMan Test V2.0
Alere q HIV-1/2 
Detect (quant PCR)calibration of the instrument, giving the signal to cut off ratio
(S/CO) [3]. The Abbott HIV Ag/Ab Combo assay (Abbott Laborato-
ries) employs a similar chemiluminescent principle.
Diagnoses considered at this stage included acute HIV infection/
seroconversion, a second window period, HIV-2 infection (with
variable sensitivity for HIV-1 and 2 on the different testing
platforms accounting for the discrepant results), or false positive
results. A second diagnostic window period in HIV serological
testing describes a time period where a fourth-generation assay
will be nonreactive because the antigen (p24) component becomes
undetectable, but before the antibody component is high enough
to be detected [4]. False positive results may be caused by non-
specific binding of other immunoglobulins in the sample to the
target antigens or antibodies or to one of the other components of
the assay. Cross-reacting immunoglobulins may represent anti-
bodies to a different antigen, rheumatoid factor or be due to
polyclonal activation.
Acute HIV infection was excluded via molecular testing, using
the COBAS1AmpliPrep/ COBAS1TaqMan HIV-1 Quantitative Test
V2.0 (Roche Diagnostics), showing a viral load of lower than
detectable. Qualitative total nucleic acid testing for HIV-1 with the
HIV-1 Qualitative Test V2.0 (Roche Diagnostics) also yielded a
negative result. (See Table 2 for details). Considering the patient’s
country of origin, a diagnosis of HIV-2 was considered, and an EDTA
whole blood sample was tested for HIV-2 via polymerase chain
reaction (PCR), using the AlereTM Q analyser HIV 1 /2 Detect test
(Roche Diagnostics), which gave negative results for both HIV 1
group M/N, group O and HIV-2.
In order to exclude established HIV infection with low or
variable antibody levels, as a result of undisclosed treatment with
antiretrovirals, or as a possible elite controller of HIV, additional
serological testing was performed. A variety of rapid immuno-
chromatographic tests were performed on the patient's samples,
all with negative results (see Table 1 for details). An alternative 4th
generation serological assay, the GS Bio-Rad HIV Combo Ag/Ab9/4 9/4 10/4 10/4 17/4
2 3 4 5 6
R R R R
488 493 415 471
NR NR NR NR
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as a tiebreaker which too produced a negative result. CD4 count
testing was performed with a result of 1 454 cells/microliter.
To investigate a non-specific cross reaction related to the Roche
Elecsys1HIV combi PT assay principle, such as non-specific cross-
linking of conjugate, tests based on the same principle but for other
serological markers for which the patient might be negative, were
investigated on the same Roche COBAS1e 601 analyser. These
included hepatitis A IgM, hepatitis B surface, and core IgM and
hepatitis C antibodies as well as hepatitis B surface antigen. The
sample tested negative with all these assays, suggesting that the
false cross-reactivity was likely restricted to a component of the
HIV combi PT assay.A series of dilutions of one of the patient
samples were made using the Roche ‘Dil Uni’ reagent and tested on
the Roche screening HIV assay. Results reflected a linear dilution of
the reactive component as follows: Undiluted sample: reactive
(S/CO 492.6); sample diluted 1:10: reactive (S/CO 48.8), sample
diluted 1:100: reactive (S/CO 4.22), sample diluted 1:1000:
reactive (S/CO 1.01). Serial dilution has been used as a method
of distinguishing false positive results due to cross reacting
antibodies from true positive results. In incidence surveys, dilution
is used to alter the sensitivity of antibody tests to detect recent HIV
infection [5]. In principle, during early HIV infection, lower
antibody titers means that reactivity can be diluted out earlier
than for samples with high titers. Low avidity, broadly reactive
antibodies produced to infectious antigens other than HIV can also
cause a false positive result in serological testing for HIV and may
theoretically become negative on dilution, as this makes a
functionally less sensitive assay [5]. It is significant in this case
that the sample tested positive on repeated dilutions, indicating
that this false positive result was most likely not due to this type of
low avidity antibody response. This finding is supported by
repeatedly positive results, with a similar S/CO result on repeat
testing 12 days after the initial sample was taken, making a
transient response to another antigen less likely.
Cross reacting Schistosoma antibodies remains a possible
cause, as the patient tested positive on an immunofluorescent
assay for anti-cercarial IgM and IgG antibodies. This has been
described as a possible cause of falsely reactive fourth generation
immunoassays in other African populations [6]. Other common
causes of cross reactivity include autoimmune disease and
rheumatoid factor; screening tests for these two conditions were
negative. To further investigate specific cross reactive antibodies,
the patient’s sample was tested with the Geenuis HIV 1/ 2
confirmatory assay (Bio-Rad Diagnostics, Marnes-la-Coquette,
France) which is a ‘rapid’ recombinant immunochromatographic
test used for the confirmation and differentiation of individual
antibody responses to HIV-1 and 2 [7]. Criteria for interpretation of
a positive test result for HIV -1 include the presence of any two
bands of the HIV-1 test lines with at least one envelope band
positive (gp160 or gp41), while a positive test for HIV-2 must
include both HIV-2 bands (gp36 and gp140). Testing of this
patient’s sample using this assay produced a faint band in the gp41
test line (HIV-1 group M and O envelope peptides) but no other
bands were produced, indicating an indeterminate result. This
correlates with findings from a report of a more than five million
samples collected over four years from low risk blood donors,
showing that the most common profile of false positive HIV-1
western blot tests were antibodies to envelope only [8].
Patient samples were sent to the screening assay manufacturer
for analysis and were found to be falsely reactive to one of the
seven HIV specific antigens the test employs. It was determined
that the COI (cut off index) of these samples was around 400, and
highly reactive against a particular synthetic peptide but non-
reactive against the recombinant antigens. The clinicians involved
were advised that it was safe to stop post exposure prophylaxis.The patient was informed about these false positive results and
advised to relate this history to future health care providers.
Discussion
Reasons for false reactive serological tests can be classified as
pre-analytical, which include sample swaps or sample contami-
nation [9]; analytical, such as false reactive results due to cross
reacting antibodies; or post-analytical, when non-reactive results
are incorrectly reported as reactive. When assays are performed in
settings that are very different from the population in which they
were validated, specificity may be lower than expected. For
instance, poor specificity has been reported for HIV and hepatitis C
virus serological assays in tropical countries [10].
Most false reactive results, however, are low positive and could
be excluded based on a low positive/indeterminate range,
appropriate for the local population. This high-positive false
positive result (more than 400 times the cut-off for positivity) on
the screening assay is therefore very unusual. It should be
emphasized that all laboratory-based HIV diagnoses require
confirmatory testing on a separate independent serological
platform and require an independently collected sample. In this
case, independently collected samples all showed high positive
values on the screening assay, but negative values on the
confirmatory assay.
Multiple biological reasons for false reactive serology have been
reported, which include polyclonal activation during systemic
infections, molecular mimicry with other infectious agents,
pregnancy, vaccination and various malignancies [11–13]. No
prior case reports regarding ameloblastoma and false positive HIV
serological results have been published, although a variety of other
malignancies have been implicated in generating false positive HIV
results [12]. The reason for the falsely reactive screening assay
result remains unknown at present, although the possibility of
cross reactivity with schistosomiasis antibodies or antibodies
produced towards his previously excised ameloblastoma, or
another antigen remains.
Conclusion
HIV serological diagnosis in adults and children older than 18
months necessitates confirmatory testing to exclude assay-specific
false reactivity and the testing of an independently collected
sample to avert sample-associated causes of false positivity such as
mislabelling, transient cross-reactivity or on-instrument contami-
nation. Although the cause for this high positive assay-specific
false reactive result could not be elucidated fully, this case
highlights the indispensable need for confirmatory HIV serological
testing and the use of independent serological and molecular
assays as tiebreakers in investigating discordant results.
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